BC Week In Review | Dec 22, 2017
Company News

Millendo to acquire Alize, gains Prader-Willi candidate

Millendo Therapeutics Inc. (Ann Arbor, Mich.) acquired Alizé Pharma S.A.S. (Lyon, France), an Alizé Pharma (Lyon, France) company, in a stock deal. Financial terms were not disclosed. The former Alizé Pharma S.A.S. facilities will maintain...
BC Week In Review | Nov 9, 2017
Clinical News

Millendo discontinues development of MLE4901

Millendo Therapeutics Inc. (Ann Arbor, Mich.) discontinued development of MLE4901 (AZD4901) after an “assessment of the clinical risks and benefits.” The company declined to disclose additional details. The neurokinin 3 receptor (TACR3; NK3R) antagonist was...
BC Week In Review | Aug 22, 2016
Clinical News

MLE4901: Phase IIb started

Millendo began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 40, 60 and 80 mg oral MLE4901 twice daily for 28 weeks in about 220 patients. The company has exclusive, worldwide rights to develop...
BC Week In Review | Aug 8, 2016
Clinical News

MLE4901: Phase IIa data

A double-blind, international Phase IIa trial in 65 patients with PCOS showed that twice-daily 40 mg MLE4901 met the primary endpoint of reducing serum LH concentration from baseline to day 7 vs. placebo (placebo-adjusted reduction...
BioCentury | Jan 11, 2016

All-in endocrine

New biological insights into Atterocor Inc .'s lone compound combined with asset sleuthing by founding VC Frazier Healthcare have morphed the company into Millendo Therapeutics Inc. , an endocrine play with a pair of first-in-class molecules...
BC Week In Review | Jan 11, 2016
Company News

AstraZeneca, Millendo Therapeutics deal

AstraZeneca granted Millendo exclusive, worldwide rights to develop and commercialize MLE4901 ( AZD4901 ). The neurokinin 3 (NK3) receptor ( TACR3 ; NK3R ) antagonist has completed a Phase IIa trial to treat polycystic ovary syndrome (PCOS). AZ...
BC Extra | Jan 6, 2016
Top Story

Millendo raises $62M series B, gains AZ asset

Millendo Therapeutics Inc. (Ann Arbor, Mich.) raised $62 in a series B round led by New Enterprise Associates. Other new investors Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund and Renaissance...
Items per page:
1 - 7 of 7